Since both sPD-L1 and IL-8 can reflect tumor burden, the combination of sPD-L1 and IL-8 may increase the accuracy of the evaluation of response to immunotherapy in NSCLC. Here, SPDL1 is linked to non-small cell lung carcinoma.